Designer drugs

Leading the Way by Sponsoring Cannabinoid Research

Retrieved on: 
Wednesday, October 21, 2020
Cannabinoid, Designer drugs

SunFlora's CEO Marcus Quinn states, "We started as a Family business in 2018, when my wife who is also co-founder and I witnessed personally the effect that cannabinoid products had on her well-being.

Key Points: 
  • SunFlora's CEO Marcus Quinn states, "We started as a Family business in 2018, when my wife who is also co-founder and I witnessed personally the effect that cannabinoid products had on her well-being.
  • It is with pride that we carve out a path for other researchers and entrepreneurs to follow."
  • "I pay close attention to what concerns the FDA and respect the work of the Dr. Lombardo and Dr. Aqua.
  • SunFlora along with the other twelve cannabinoid product companies sponsoring this research have invested in the study because we believe that the science will validate what we already know and will shift the focus from the need for research to implementing industry-wide standards to ensure product safety while at the same time advancing the science.

Global 1,4 Butanediol Market Report to 2024 - Trends, Forecast and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 13, 2020
Chemicals, Plastics, Manufacturing, Psychoactive drugs, Alkanediols, Designer drugs, Neurochemistry, Sedatives, Drugs, 1,4-Butanediol, Prodrugs, Butanediol

Some of the features of 'Global 1,4 Butanediol Market 2019-2024: Trends, Forecast, and Opportunity Analysis' include

Key Points: 
  • Some of the features of 'Global 1,4 Butanediol Market 2019-2024: Trends, Forecast, and Opportunity Analysis' include
    Market size estimates: Global 1,4 butanediol market size estimation in terms of value ($M) shipment.
  • Segmentation analysis: Global market size by technology, application, and region
    Regional analysis: Global 1,4 butanediol market breakdown by North America, Europe, Asia Pacific, and the Rest of the World
    Growth opportunities: Analysis on growth opportunities in different applications and regions for 1,4 butanediol in the global 1,4 butanediol market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, 1,4 butanediol in the global 1,4 butanediol market.
  • This report answers the following 11 key questions:
    What are some of the most promising potential, high-growth opportunities for the global 1,4 butanediol market by technology, application, and region?

New Clinical Pharmacokinetic Study Demonstrates Proof-of-Concept for Receptor Life Science’s Investigational Cannabinoid-based Product Candidates

Retrieved on: 
Monday, September 14, 2020
Cannabinoids, Designer drugs, Medication, Pharmaceutical industry, Health, Drugs, Natural sciences, Antiemetics, Phenols

The effectiveness of cannabinoid medicines is negatively impacted by poor bioavailability, highly variable absorption, and erratic time to onset, said Dr. Andrea Leone-Bay, PhD, Chief Scientific Officer and a founder of Receptor Life Sciences.

Key Points: 
  • The effectiveness of cannabinoid medicines is negatively impacted by poor bioavailability, highly variable absorption, and erratic time to onset, said Dr. Andrea Leone-Bay, PhD, Chief Scientific Officer and a founder of Receptor Life Sciences.
  • We are developing solid dosage therapeutics, both oral and inhaled, designed to address these cannabinoid delivery challenges.
  • The Receptor Life Sciences team brings over 100 years of pharmaceutical industry expertise to the pursuit of FDA regulated, standardized cannabinoid therapies.
  • The Company is developing synthetic cannabinoid drug candidates combined with FDA-cleared, proven drug delivery technologies to overcome known hurdles to cannabinoid-derived therapies.

Bio-Succinic Acid Market Size is Expected to Grow at a CAGR of 15.7% - Valuates Reports

Retrieved on: 
Friday, August 21, 2020
Psychoactive drugs, Chemical compounds, Organic compounds, Polyesters, Thermoplastics, Sedatives, Designer drugs, Dicarboxylic acids, Succinic acid, gamma-Butyrolactone, PBT, Acids in wine

The Global bio succinic acid market size was valued at USD 185.6 Million in 2019 and is expected to grow at a CAGR of 15.7% over the forecast period 2020-2026.

Key Points: 
  • The Global bio succinic acid market size was valued at USD 185.6 Million in 2019 and is expected to grow at a CAGR of 15.7% over the forecast period 2020-2026.
  • The main factors driving the bio-succinic acid market size arevolatility in fossil fuel prices, an increase in carbon footprints, and an increase in preference for using raw materials available locally.
  • Increasing demand for BDO and its derivatives, including Tetrahydrofuran ( THF), Gamma-Butyrolactone (GBL), and Polybutylene Terephthalate (PBT), is expected to fuel the growth of bio-succinic acid market size.
  • In 2013, Europe held the largest bio-succinic acid market share and is expected to continue its dominance during the forecast period.

Bio-Succinic Acid Market Size is Expected to Grow at a CAGR of 15.7% - Valuates Reports

Retrieved on: 
Friday, August 21, 2020
Psychoactive drugs, Chemical compounds, Organic compounds, Polyesters, Thermoplastics, Sedatives, Designer drugs, Dicarboxylic acids, Succinic acid, gamma-Butyrolactone, PBT, Acids in wine

The Global bio succinic acid market size was valued at USD 185.6 Million in 2019 and is expected to grow at a CAGR of 15.7% over the forecast period 2020-2026.

Key Points: 
  • The Global bio succinic acid market size was valued at USD 185.6 Million in 2019 and is expected to grow at a CAGR of 15.7% over the forecast period 2020-2026.
  • The main factors driving the bio-succinic acid market size arevolatility in fossil fuel prices, an increase in carbon footprints, and an increase in preference for using raw materials available locally.
  • Increasing demand for BDO and its derivatives, including Tetrahydrofuran ( THF), Gamma-Butyrolactone (GBL), and Polybutylene Terephthalate (PBT), is expected to fuel the growth of bio-succinic acid market size.
  • In 2013, Europe held the largest bio-succinic acid market share and is expected to continue its dominance during the forecast period.

Annual accounts 2019

Retrieved on: 
Thursday, July 9, 2020
Psychoactive drugs, European Monitoring Centre for Drugs and Drug Addiction, European Union, Designer drugs, Drug control law, Cannabinoids, European Coalition for Just and Effective Drug Policies, João Castel-Branco Goulão

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>

Key Points: 

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. Read more >>

CB Therapeutics Achieves Another Breakthrough with the Biosynthesis of DMT and Related Tryptamine-based Compounds

Retrieved on: 
Wednesday, June 3, 2020
Mental health, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Amines, Psychoactive drugs, Entheogens, Ayahuasca, N,N-Dimethyltryptamine, Tryptamines, Designer drugs

CB Therapeutics, Inc. has achieved the first successful biosynthesis of DMT (N,N Dimethyltryptamine) and related tryptamine-based compounds in yeast and has filed a patent on their biosynthetic production process for DMT and related analogs.

Key Points: 
  • CB Therapeutics, Inc. has achieved the first successful biosynthesis of DMT (N,N Dimethyltryptamine) and related tryptamine-based compounds in yeast and has filed a patent on their biosynthetic production process for DMT and related analogs.
  • These proprietary production processes will support clinical trials for these compounds as therapeutics, and potentially their commercialization.
  • We continue to advance our research and development for the biosynthetic production of these compounds, said Dr. Jacob Vogan, CSO at CB Therapeutics.
  • The CB Therapeutics platform can not only make the active compounds and phytochemicals that occur naturally, but by using enzymatic processes CB Therapeutics has been able to create bio-identical compounds as well as their analogs.

Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules

Retrieved on: 
Tuesday, May 5, 2020
Psychoactive drugs, Designer drugs, Cannabinoids

AXIM also found similar reaction pathways for creating multi-cannabinoid molecules, where different cannabinoids are incorporated into one chemical entity.

Key Points: 
  • AXIM also found similar reaction pathways for creating multi-cannabinoid molecules, where different cannabinoids are incorporated into one chemical entity.
  • Through this invention, AXIM is providing a solution to several challenges that scientists currently face in the development of cannabinoid products and therapies.
  • "We hope to provide a solution to cannabinoid water solubility that will allow for the innovation of many new products through this patent application."
  • Founded in 2014, AXIM Biotechnologies, Inc. (AXIM) is a world leader in the research and development of plant and laboratory-derived cannabinoid and oncological therapeutics.

Emerald Health Pharmaceuticals’ Lead Product Candidate Determined Not to be a Controlled Substance in Canada

Retrieved on: 
Monday, March 23, 2020
Designer drugs, Medication, Cannabinoids, Natural sciences, Health, Chemistry

SAN DIEGO, CA, March 23, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has received the determination from Canadas Controlled Substances Directorate that its lead product candidate, EHP-101, is not a controlled substance under its Controlled Drug and Substance Act (CDSA).

Key Points: 
  • SAN DIEGO, CA, March 23, 2020 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has received the determination from Canadas Controlled Substances Directorate that its lead product candidate, EHP-101, is not a controlled substance under its Controlled Drug and Substance Act (CDSA).
  • These determinations by Canada and the US also highlight the important difference between our novel molecules compared to natural cannabinoids.
  • In general, the determination of not being a controlled substance eliminates the costs and complexities otherwise associated with developing controlled substances.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing novel product candidates derived from cannabinoids for the treatment of CNS, autoimmune, fibrotic and other diseases.

Receptor Life Sciences Secures U.S. Patent for its Oral Absorption Enhancing Excipients with Cannabinoids

Retrieved on: 
Thursday, March 19, 2020
Pharmaceutical industry, Health, Pharmaceutical sciences, Excipient, Medication, Designer drugs, Cannabinoids, Antiemetics

SEATTLE, March 19, 2020 (GLOBE NEWSWIRE) -- Receptor Life Sciences (RLS), a leading biopharmaceutical company developing FDA regulated oral and inhaled cannabinoid medicines, today announced that the United States Patent and Trademark Office has issued the Company a Patent for compositions comprising cannabinoids and the companys oral absorption enhancing excipients: U.S. Patent No.

Key Points: 
  • SEATTLE, March 19, 2020 (GLOBE NEWSWIRE) -- Receptor Life Sciences (RLS), a leading biopharmaceutical company developing FDA regulated oral and inhaled cannabinoid medicines, today announced that the United States Patent and Trademark Office has issued the Company a Patent for compositions comprising cannabinoids and the companys oral absorption enhancing excipients: U.S. Patent No.
  • Receptors excipients increase oral cannabinoid bioavailability, reduce time to onset and can be formulated as either liquid or solid dosage forms.
  • This patent provides strong patent coverage for RLS oral delivery technology platform, said Greg Wesner, Founder, CEO, and General Counsel, Receptor Life Sciences.
  • The patent provides a broad and versatile foundation for the development of a disruptive product line in oral cannabinoid medicines.